Jérôme Dauba

4.3k citations

54 papers · 1.3k indexed · h-index 14

Impact in

Geriatrics and Gerontology top 1%
- Frailty in Older Adults
Oncology top 5%
- Cancer survivorship and care
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology

Papers in ⓘ

Geriatrics and Gerontology 7
- Frailty in Older Adults 7
Oncology 41
- Cancer Treatment and Pharmacology 22
- Colorectal Cancer Treatments and Studies 21
- Cancer survivorship and care 7
- Pancreatic and Hepatic Oncology Research 5

Co-authors: Pierre Soubeyran (10 shared papers)Laurent Cany (8 shared papers)J. Ceccaldi (8 shared papers)C. Blanc-Bisson (7 shared papers)Jean‐Frédéric Blanc (5 shared papers)Nadine Houédé (4 shared papers)Marianne Fonck (10 shared papers)C. Mertens (6 shared papers)
Journals: Journal of Clinical Oncology (26 papers)Annals of Oncology (7 papers)European Journal of Cancer (3 papers)Cancer Research (2 papers)Cancer (1 paper)
Partner nations: France Austria Canada

In The Last Decade

Jérôme Dauba

52 papers receiving 1.3k citations

Peers

Countries citing papers authored by Jérôme Dauba

Since Specialization

Citations

This map shows the geographic impact of Jérôme Dauba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jérôme Dauba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jérôme Dauba more than expected).

Fields of papers citing papers by Jérôme Dauba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jérôme Dauba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jérôme Dauba. The network helps show where Jérôme Dauba may publish in the future.

Co-authors

The 25 scholars most cited alongside Jérôme Dauba, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jérôme Dauba Line = papers co-authored together Jérôme Dauba links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer Journal of Clinical Oncology ·Pierre Soubeyran, Marianne Fonck, C. Blanc-Bisson, Jean‐Frédéric Blanc, J. Ceccaldi, C. Mertens, Y. Imbert, Laurent Cany, Luc Vogt, Jérôme Dauba, Francis Andriamampionona, Nadine Houédé, Anne Floquet, François Chomy, Véronique Brouste, Alain Ravaud, Carine Bellera, M. Rainfray	2012	305
2	Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018 Journal of Thoracic Oncology ·Florian Guisier, Catherine Dubos‐Arvis, F. Viñas, H. Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Massimo Bernardi, P. Fournel, R. Lamy, M. Pérol, Jérôme Dauba, Gilles Gonzales, L. Falchero, C. Decroisette, Pascal Assouline, C. Chouaïd, Olivier Bylicki	2020	215
3	Functional Decline in Older Patients With Cancer Receiving First-Line Chemotherapy Journal of Clinical Oncology ·Stéphanie Hoppe, M. Rainfray, Marianne Fonck, Laurent Hoppenreys, Jean‐Frédéric Blanc, J. Ceccaldi, C. Mertens, C. Blanc-Bisson, Y. Imbert, Laurent Cany, Luc Vogt, Jérôme Dauba, Nadine Houédé, Carine Bellera, Anne Floquet, Marie-Noëlle Fabry, Alain Ravaud, Camille Chakiba, Simone Mathoulin‐Pélissier, Pierre Soubeyran	2013	174
4	Nutritional Advice in Older Patients at Risk of Malnutrition during Treatment for Chemotherapy: A Two-Year Randomized Controlled Trial PLoS ONE ·Isabelle Bourdel‐Marchasson, C. Blanc-Bisson, A. Doussau, Christine Germain, Jean‐Frédéric Blanc, Jérôme Dauba, C. Lahmar, Éric Terrebonne, Cédric Lecaille, J. Ceccaldi, Laurent Cany, Sandrine Lavau‐Denès, Nadine Houédé, François Chomy, J. Durrieu, Pierre Soubeyran, Pierre Sénesse, Geneviève Chêne, Mariane Fonck	2014	98
5	Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO) Annals of Oncology ·Alain Lortholary, R. Largillier, B. Weber, Laurence Gladieff, J. Alexandre, Xavier Durando, B. Slama, Jérôme Dauba, D. Paraïso, Éric Pujade-Lauraine	2011	71
6	Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR) Journal of Clinical Oncology ·Jean-François Delattre, Romain Cohen, Julie Henriques, Antoine Falcoz, Jean‐François Emile, Serge Fratté, Benoist Chibaudel, Jérôme Dauba, Olivier Dupuis, Y. Bécouarn, Frédéric Bibeau, Julien Taı̈eb, Christophe Louvet, Déwi Vernerey, Thierry André, Magali Svrcek	2020	55
7	Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology ·Élisabeth Quoix, J.P. Oster, V. Westeel, Éric Pichon, Gérard Zalcman, Laurence Baudrin, A. Lavolé, Jérôme Dauba, Marie-Paule Lebitasy, B. Milleron, (unknown)	2010	46
8	Effects of a physical activity programme to prevent physical performance decline in onco‐geriatric patients: a randomized multicentre trial Journal of Cachexia Sarcopenia and Muscle ·Haritz Arrieta, Cyril Astrugue, Sophie Regueme, J. Durrieu, Aline Maillard, Alban Rieger, Éric Terrebonne, Alexis Laurent, Brigitte Maget, V. Servent, Sandrine Lavau‐Denès, Jérôme Dauba, Marianne Fonck, Rodolphe Thiébaut, Isabelle Bourdel‐Marchasson	2019	41
9	Effectiveness of cold cap in the prevention of docetaxel-induced alopecia European Journal of Cancer ·M. Lemenager, S Lecomte, M.-E. Bonneterre, E.H. Bessa, Jérôme Dauba, Jacques Bonneterre	1997	37
10	Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy and safety results of the International GERCOR DREAM phase III trial. Journal of Clinical Oncology ·Christophe Tournigand, Benoît Samson, Werner Scheithauer, Gérard Lledo, F. Viret, Thierry André, Jean François Ramée, N. Tubiana-Mathieu, Jérôme Dauba, Olivier Dupuis, Yves Rinaldi, May Mabro, Nathalie Aucoin, Ahmed Khalil, Jean Latreille, Christophe Louvet, David Brusquant, Franck Bonnetain, Benoist Chibaudel, Aimery de Gramont, (unknown)	2012	29
11	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial The Lancet. Gastroenterology & hepatology ·Jean‐Baptiste Bachet, Pascal Hammel, Jérôme Desrame, Aurélia Meurisse, Benoist Chibaudel, Thierry André, P. Debourdeau, Jérôme Dauba, Thierry Lecomte, Jean‐François Seitz, Christophe Tournigand, Thomas Aparicio, Véronique Guérin Meyer, Julien Taı̈eb, Julien Volet, Amandine Monier, Franck Bonnetain, Christophe Louvet	2017	26
12	Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first‐line therapy for triple‐negative, metastatic, or locally advanced breast cancer: Results from the GINECO A‐TaXel phase 2 study Cancer ·Jean‐Marc Ferrero, Anne‐Claire Hardy‐Bessard, Olivier Capitain, Alain Lortholary, Bruno César Corrêa Salles, Philippe Follana, Robert Hervé, Mathilde Deblock, Jérôme Dauba, Mustapha Atlassi, Rémy Largillier	2016	26
13	A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study Annals of Oncology ·Olivier Trédan, Philippe Follana, Isabelle Moullet, Claire Cropet, S. Trager-Maury, Jérôme Dauba, Sandrine Lavau‐Denès, Véronique Dièras, Dominique Beal-Ardisson, Marie-Claude Gouttebel, Hubert Orfeuvre, Laëtitia Stefani, Christelle Jouannaud, F Bürki, Thierry Petit, Emmanuel Guardiola, Celia Roemer Becuwe, Emmanuel Blot, Éric Pujade-Lauraine, Thomas Bachelot	2016	19
14	Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy European Respiratory Journal ·Frédéric Fiteni, Amélie Anota, Franck Bonnetain, Jean-Philippe Oster, Éric Pichon, Marie Wislez, Jérôme Dauba, D. Debieuvre, Pierre-Jean Souquet, L. Bigay-Gamé, Olivier Molinier, Éric Dansin, M. Poudenx, B. Milleron, Franck Morin, Gérard Zalcman, Élisabeth Quoix, Virginie Westeel	2016	14
15	Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: A first-line phase II study Clinics and Research in Hepatology and Gastroenterology ·Marianne Fonck, René Brunet, Y. Bécouarn, Jean-Louis Legoux, Jérôme Dauba, Laurent Cany, Denis Smith, Dominique Auby, Éric Terrebonne, L Traissac, C. Mertens, Pierre Soubeyran, Carine Bellera, M. Rainfray, Simone Mathoulin‐Pélissier	2011	12
16	Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter? European Journal of Cancer ·Damien Pouessel, Sylvie Chevret, Frédéric Rolland, Gwénaëlle Gravis, L. Geoffrois, Guilhem Roubaud, Safae Terrisse, Helen Boyle, Christine Chevreau, Jérôme Dauba, Guillaume Moriceau, Ingrid Alexandre, G. Deplanque, Angélique Chapelle, Élodie Vauléon, A. Colau, François Audenet, Thomas Grellety, Stéphane Culine	2015	11
17	Rebecca: a Large Cohort Study of Regorafenib (Reg) in the Real-Life Setting in Patients (Pts) Previously Treated for Metastatic Colorectal Cancer (Mcrc) Annals of Oncology ·David Tougeron, Françoise Desseigne, Pierre Étienne, Louis-Marie Dourthe, Laurent Mineur, Bernard Paule, Antoine Hollebecque, Emmanuelle Tresch, D. Spaëth, Pierre Michel, Jérôme Dauba, P. Laplaige, Christophe Borg, Dominique Béchade, Stéphanie Clisant, Jean–Marc Phelip, Arnaud de la Fouchardière, Thierry André, Antoine Adenis	2014	11
18	Vefora, GETUG-AFU V06 study: Randomized multicenter phase II/III trial of fractionated cisplatin (CI)/gemcitabine (G) or carboplatin (CA)/g in patients (pts) with advanced urothelial cancer (UC) with impaired renal function (IRF)—Results of a planned interim analysis. Journal of Clinical Oncology ·Loı̈c Mourey, Aude Fléchon, Diégo Tosi, Sophie Abadie Lacourtoisie, Florence Joly, Aline Guillot, Yohann Loriot, Jérôme Dauba, Guilhem Roubaud, Frédéric Rolland, Christine L. Abraham, Hélène Gauthier, Philippe Barthélémy, Gwénaëlle Gravis, Soazig Nénan-Le Ficher, Bastien Cabarrou, Thomas Filleron	2020	10
19	Prediction of early death risk in the elderly with cancer: Results of a prospective multicentric study of 364 patients under chemotherapy Journal of Clinical Oncology ·Pierre Soubeyran, M. Rainfray, Simone Mathoulin‐Pélissier, C. Blanc-Bisson, C. Mertens, Julie Blanc, J. Ceccaldi, Y. Imbert, Jérôme Dauba, Marianne Fonck	2007	10
20	Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results Annals of Oncology ·Julien Taı̈eb, Franck Bonnetain, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Roger Faroux, Serge Fratté, Jérôme Dauba, Déwi Vernerey, Christophe Louvet, Céline Lepère, Olivier Dupuis, Y. Bécouarn, May Mabro, Joëlle Egreteau, Olivier Bouché, G. Deplanque, Marc Ychou, Aimery de Gramont, Thierry André	2017	9

About Jérôme Dauba

Jérôme Dauba is a scholar working on Geriatrics and Gerontology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Dermatology, having authored 54 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (22 papers), Colorectal Cancer Treatments and Studies (21 papers), Lung Cancer Treatments and Mutations (10 papers), Nutrition and Health in Aging (8 papers), Gastric Cancer Management and Outcomes (8 papers), Frailty in Older Adults (7 papers), Cancer survivorship and care (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). The work is most often cited by research in Geriatrics and Gerontology (363 citations), Oncology (738 citations), Pulmonary and Respiratory Medicine (497 citations), Physiology (355 citations) and Reproductive Medicine (70 citations). Jérôme Dauba has collaborated with scholars based in France, Austria and Canada. Frequent co-authors include Pierre Soubeyran, Laurent Cany, J. Ceccaldi, C. Blanc-Bisson, Jean‐Frédéric Blanc, Nadine Houédé, Marianne Fonck, C. Mertens, M. Rainfray and Y. Imbert. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Cancer Research and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact